Abstract：Acute myocardial infarction (AMI) is one of the major critical diseases of the cardiovascular system with sudden onset and high mortality. Although the inhospital mortality rate of AMI patients has been reduced due to the continuously improved and optimized therapeutic regimen, the incidence of major adverse cardiovascular events is still significantly high. Therefore, further optimizing the therapeutic regimen and treatment strategy for AMI is still urgently needed by clinicians. This paper reviews from the following aspects including the balance between the bleeding risk and ischemic risk in the use of antiplatelet aggregation drugs after AMI, the residual microcirculation disorder in the opening of infarct related arteries, the timing of handling noninfarct related blood vessels, disease evaluation before other secondary preventive treatment, and the long-term benefits from mechanicallyassisted treatment.
